See more : Top Glove Corporation Bhd. (TGLVY) Income Statement Analysis – Financial Results
Complete financial analysis of Prothena Corporation plc (PRTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Prothena Corporation plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Banco Santander México, S.A., Institución de Banca Múltiple, Grupo Financiero Santander México (BSMX) Income Statement Analysis – Financial Results
- Theraclion SA (ALTHE.PA) Income Statement Analysis – Financial Results
- PT Guna Timur Raya Tbk (TRUK.JK) Income Statement Analysis – Financial Results
- Generation Bio Co. (GBIO) Income Statement Analysis – Financial Results
- Eurazeo SE (EUZOF) Income Statement Analysis – Financial Results
Prothena Corporation plc (PRTA)
About Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 91.37M | 53.91M | 200.58M | 853.00K | 814.00K | 955.00K | 27.52M | 1.06M | 1.61M | 50.85M | 676.00K | 2.66M | 507.00K | 1.24M |
| Cost of Revenue | 220.57M | 6.74M | 82.28M | 74.88M | 50.84M | 101.18M | 134.55M | 119.53M | 58.44M | 38.45M | 26.05M | 34.14M | 0.00 | 0.00 |
| Gross Profit | -129.20M | 47.16M | 118.29M | -74.03M | -50.02M | -100.23M | -107.03M | -118.48M | -56.83M | 12.40M | -25.38M | -31.48M | 507.00K | 1.24M |
| Gross Profit Ratio | -141.40% | 87.49% | 58.98% | -8,678.90% | -6,145.21% | -10,495.08% | -388.92% | -11,230.24% | -3,536.53% | 24.39% | -3,753.85% | -1,184.39% | 100.00% | 100.00% |
| Research & Development | 220.57M | 135.56M | 82.28M | 74.88M | 50.84M | 101.18M | 134.55M | 119.53M | 58.44M | 38.45M | 26.05M | 34.14M | 24.17M | 9.79M |
| General & Administrative | 61.84M | 49.90M | 46.32M | 38.70M | 35.74M | 42.48M | 48.23M | 41.06M | 23.11M | 19.05M | 15.05M | 9.93M | 5.58M | 3.62M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 61.84M | 49.90M | 46.32M | 38.70M | 35.74M | 42.48M | 48.23M | 41.06M | 23.11M | 19.05M | 15.05M | 9.93M | 5.58M | 3.62M |
| Other Expenses | 0.00 | 5.95M | -54.00K | 1.31M | 8.40M | 2.74M | -2.35M | 571.00K | 26.00K | 310.00K | -225.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 282.41M | 185.46M | 128.60M | 113.59M | 86.57M | 143.67M | 182.77M | 160.59M | 81.54M | 57.50M | 41.10M | 44.07M | 29.75M | 13.41M |
| Cost & Expenses | 282.41M | 185.46M | 128.60M | 113.59M | 86.57M | 143.67M | 182.77M | 160.59M | 81.54M | 57.50M | 41.10M | 44.07M | 29.75M | 13.41M |
| Interest Income | 31.01M | 6.35M | 42.00K | 1.37M | 8.20M | 6.39M | 3.55M | 0.00 | 196.00K | 79.00K | 71.00K | 5.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 8.20M | 3.70M | 3.69M | 0.00 | 0.00 | 0.00 | 154.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 928.00K | 6.74M | 6.80M | 6.98M | 6.82M | 3.22M | 3.07M | 2.43M | 806.00K | 743.00K | 660.00K | 468.00K | 391.00K | 191.00K |
| EBITDA | -190.11M | -131.56M | 71.98M | -111.22M | -78.94M | -152.90M | -152.19M | -156.54M | -79.13M | -5.91M | -39.77M | -40.94M | -28.85M | -11.97M |
| EBITDA Ratio | -208.06% | -244.05% | 35.88% | -13,216.18% | -10,542.87% | -13,252.88% | -564.17% | -15,121.80% | -4,974.30% | -13.07% | -5,980.33% | -1,557.94% | -5,690.93% | -963.07% |
| Operating Income | -191.04M | -131.56M | 71.98M | -112.73M | -85.70M | -158.86M | -155.25M | -159.54M | -79.94M | -6.65M | -40.43M | -41.41M | -29.24M | -12.16M |
| Operating Income Ratio | -209.08% | -244.05% | 35.88% | -13,216.18% | -10,527.89% | -16,634.03% | -564.17% | -15,121.80% | -4,974.30% | -13.07% | -5,980.33% | -1,557.94% | -5,768.05% | -978.44% |
| Total Other Income/Expenses | 30.56M | 5.95M | -54.00K | 1.31M | 8.40M | 2.74M | -2.35M | 571.00K | 26.00K | 310.00K | -154.00K | 5.00K | 0.00 | 0.00 |
| Income Before Tax | -160.48M | -125.61M | 71.92M | -111.43M | -77.30M | -156.12M | -157.60M | -158.96M | -79.91M | -6.34M | -40.58M | -41.41M | -29.24M | -12.16M |
| Income Before Tax Ratio | -175.64% | -233.01% | 35.86% | -13,062.95% | -9,496.07% | -16,347.12% | -572.71% | -15,067.68% | -4,972.68% | -12.47% | -6,003.11% | -1,557.75% | -5,768.05% | -978.44% |
| Income Tax Expense | -13.45M | -8.66M | 4.95M | -283.00K | 379.00K | -470.00K | -4.37M | 1.14M | 701.00K | 811.00K | 415.00K | 6.00K | 426.00K | 320.00K |
| Net Income | -147.03M | -116.95M | 66.98M | -111.14M | -77.68M | -155.65M | -153.24M | -160.11M | -80.61M | -7.15M | -41.00M | -41.41M | -29.67M | -12.48M |
| Net Income Ratio | -160.91% | -216.95% | 33.39% | -13,029.78% | -9,542.63% | -16,297.91% | -556.84% | -15,176.11% | -5,016.30% | -14.06% | -6,064.50% | -1,557.98% | -5,852.07% | -1,004.18% |
| EPS | -2.76 | -2.47 | 1.51 | -2.78 | -1.95 | -3.93 | -4.07 | -4.66 | -2.66 | -0.29 | -2.20 | -2.84 | -1.68 | -0.71 |
| EPS Diluted | -2.76 | -2.47 | 1.38 | -2.78 | -1.95 | -3.93 | -4.07 | -4.66 | -2.66 | -0.29 | -2.20 | -2.84 | -1.68 | -0.71 |
| Weighted Avg Shares Out | 53.22M | 47.37M | 44.23M | 39.92M | 39.88M | 39.56M | 37.65M | 34.35M | 30.33M | 24.67M | 18.62M | 14.59M | 17.68M | 17.68M |
| Weighted Avg Shares Out (Dil) | 53.22M | 47.37M | 48.46M | 39.92M | 39.88M | 39.56M | 37.65M | 34.35M | 30.33M | 24.67M | 18.62M | 14.59M | 17.68M | 17.68M |
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts
7 A-Rated Biotechs to Buy for the Long Run
Prothena: A Biotech Company With A Promising Pipeline
An Alzheimer's Bubble That Was Well & Truly Burst May Be Blowing Up Again - Here's Why
Prothena (PRTA) Q3 Earnings Miss, Pipeline Progress in Focus
Prothena (PRTA) Q3 Earnings and Revenues Miss Estimates
7 A-Rated Healthcare Stocks to Buy for the Long Haul
VRTX vs. PRTA: Which Stock Is the Better Value Option?
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Prothena Announces Executive Appointments
Source: https://incomestatements.info
Category: Stock Reports